Coronavirus vaccine: India begins world’s biggest drive

But concerns have been raised over the efficacy of Covaxin because the

regulator’s emergency approval came before the completion of Phase 3 clinical trials. The regulator and the manufacturer have said the vaccine is safe, and that the efficacy data would be available by February.